Professor Sir Peter Horby
Contact information
Muriel Lunn
Podcast interview
Emerging infectious diseases
Research on emerging infectious diseases can only be conducted during outbreaks. Although virology has improved, a well calibrated and effective public health response is often lacking. Epidemiological and clinical research as well as mathematical modelling will give us answers during the epidemics and help us provide better diagnostics and better treatments.
Peter Horby
FMedSci
Moh Family Foundation Professor of Emerging Infections and Global Health
- Director, Pandemic Sciences Institute
- Executive Director, ISARIC
Pandemic Sciences Institute
Sir Peter Horby is Moh Family Foundation Professor of Emerging Infections and Global Health at the University of Oxford and the Director of the Pandemic Sciences Institute. The Pandemic Sciences Institute is a multidisciplinary initiative to create collaborative science-driven solutions to identify, prepare for, and counter pandemic threats. He is also Executive Director of the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC), a consortium of international, national and local research networks whose research activities span 134 countries worldwide.
He is Co-Chief Investigator of the RECOVERY trial of treatments for viral pneumonia.
He has advised the World Health Organisation, the UK Government and other agencies on epidemic preparedness, clinical research and clinical trial design for epidemic infectious diseases.
He is the former, and founding, Director of the Oxford University Clinical Research Unit in Hanoi, Vietnam. The unit was established in early 2006 and conducts research on infectious diseases which crosses the disciplines of basic science, medical science and public health.
RECOVERY trial results
Effect of dexamethasone on 28-day mortality in severe COVID-19.
Recent publications
-
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Journal article
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
-
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2024)
-
14.1 In Practice: RECOVERY Trial
Chapter
Horby P. et al, (2024), Principles and Practice of Emergency Research Response
-
In Practice: RECOVERY Trial
Chapter
Horby P. et al, (2024), Principles and Practice of Emergency Research Response
-
Group sequential designs for clinical trials when the maximum sample size is uncertain.
Journal article
Yarahmadi A. et al, (2024), Stat Med